Key result
Early sacubitril/valsartan after STEMI is linked to ~2.8-fold higher odds of favorable LV remodeling.
Why the study?
Adverse left ventricular remodeling remains a major determinant of heart failure and mortality after STEMI despite primary PCI, and evidence regarding early initiation of sacubitril/valsartan following STEMI remains limited.
Does early initiation of sacubitril/valsartan within 7 days of STEMI improve infarct size markers and left ventricular remodeling compared with standard ACEI/ARB therapy in patients undergoing primary PCI?
Cohort (n=150)
No
Does early initiation of sacubitril/valsartan within 7 days of STEMI improve infarct size markers and left ventricular remodeling compared with standard ACEI/ARB therapy in patients undergoing primary PCI?
In this real-world retrospective cohort of STEMI patients undergoing primary PCI, early initiation of sacubitril/valsartan within 7 days was feasible, well tolerated, and associated with reduced adverse left ventricular remodeling and improved LVEF recovery compared with standard ACEI/ARB therapy.
Answers are grounded in this paper and cite their sources.
Early sacubitril/valsartan after STEMI associated with less adverse remodeling; hypothesis-generating and requires RCTs before practice change.
Background: Adverse left ventricular remodeling remains a major determinant of heart failure and mortality in patients with ST-elevation myocardial infarction (STEMI) despite successful primary percutaneous coronary intervention (PCI). Sacubitril/valsartan has shown beneficial effects on ventricular remodeling in heart failure populations; however, evidence regarding its early initiation following STEMI remains limited. Objectives: To evaluate the association of early sacubitril/valsartan initiation with infarct-size markers and ventricular remodeling outcomes in STEMI patients undergoing primary PCI. Methods: This retrospective observational cohort study included 150 consecutive STEMI patients treated with primary PCI at Tianjin Hospital, China, between January 2020 and December 2024. Patients were categorized into an angiotensin receptor–neprilysin inhibitor (ARNI) group receiving sacubitril/valsartan within 7 days of STEMI or a control group receiving standard ACEI/ARB therapy. Ventricular remodeling was assessed using serial echocardiographic measurements including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). Clinical outcomes were evaluated with a minimum follow-up of 6 months. Results: Baseline demographic and procedural characteristics were comparable between groups. Patients receiving early sacubitril/valsartan demonstrated lower peak cardiac biomarker levels and greater improvement in follow-up LVEF compared with the control group. Adverse ventricular remodeling occurred less frequently in the ARNI group. Heart failure–related hospitalizations were lower among patients receiving sacubitril/valsartan, whereas all-cause mortality and adverse event rates were comparable between groups. Multivariable analysis demonstrated that early sacubitril/valsartan initiation was associated with favorable ventricular remodeling. Conclusion: Early sacubitril/valsartan initiation after STEMI treated with primary PCI was associated with improved ventricular remodeling and better recovery of left ventricular systolic function in this retrospective cohort. These findings should be considered hypothesis-generating and require confirmation in larger prospective randomized studies.
No takes yet. Share an insight, caveat, or question.
Lei Sun (2026) conducted a cohort in ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) (n=150). Early sacubitril/valsartan initiation (within 7 days of STEMI) vs. Standard ACEI/ARB therapy was evaluated on Favorable/adverse ventricular remodeling (adverse remodeling defined as increase in LVEDV >=20% from baseline and/or failure of LVEF improvement during follow-up) (OR 2.84, 95% CI 1.42-5.67, p=0.003). Early sacubitril/valsartan initiation after STEMI and primary PCI reduced adverse LV remodeling and increased odds of favorable remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: